Literature DB >> 15240561

Cell surface sialic acids do not affect primary CD22 interactions with CD45 and surface IgM nor the rate of constitutive CD22 endocytosis.

Mai Zhang1, Ajit Varki.   

Abstract

CD22/Siglec-2 is a B cell-specific molecule modulating surface IgM (sIgM) signaling via cytosolic tyrosine-based motifs. CD22 recognizes alpha2-6-linked sialic acids (Sias) via an amino-terminal Ig-like domain. This Sia-binding site is typically masked by unknown sialylated ligands on the same cell surface, an interaction required for optimal signaling function. We studied the effect of cell surface Sias on specific interactions of CD22 with other molecules and on its turnover via endocytosis. A novel approach for simultaneous biotinylation and cross-linking showed that CD22 associates with CD45 and sIgM at much higher levels than reported in prior studies, possibly involving cell surface multimers of CD22. Sia removal or mutation of a CD22 arginine residue required for Sia recognition did not affect these associations even in human:mouse heterologous systems, indicating that they are primarily determined by evolutionarily conserved protein-protein interactions. Thus masking of the Sia-binding site of CD22 involves many cell surface sialoglycoproteins, without requiring specific ligand(s) and/or is mediated by secondary interactions with Sias on CD45 and sIgM. Abrogating Sia interactions also does not affect constitutive CD22 endocytosis. Sia removal does enhance the much faster rate of anti-CD22 antibody-triggered endocytosis, as well as killing by an anti-CD22 immunotoxin. In contrast to the unstimulated state, sIgM cross-linking inhibits both antibody-induced endocytosis and immunotoxin killing. Thus the signal- modulating activity of CD22 Sia recognition cannot be explained by mediation of primary interactions with specific molecules, nor by effects on constitutive endocytosis. The effects on antibody-mediated endocytosis could be of relevance to immunotoxin treatment of lymphomas.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15240561     DOI: 10.1093/glycob/cwh126

Source DB:  PubMed          Journal:  Glycobiology        ISSN: 0959-6658            Impact factor:   4.313


  24 in total

Review 1.  Siglecs as sensors of self in innate and adaptive immune responses.

Authors:  James C Paulson; Matthew S Macauley; Norihito Kawasaki
Journal:  Ann N Y Acad Sci       Date:  2012-01-30       Impact factor: 5.691

2.  ST6Gal-I restrains CD22-dependent antigen receptor endocytosis and Shp-1 recruitment in normal and pathogenic immune signaling.

Authors:  Prabhjit K Grewal; Mark Boton; Kevin Ramirez; Brian E Collins; Akira Saito; Ryan S Green; Kazuaki Ohtsubo; Daniel Chui; Jamey D Marth
Journal:  Mol Cell Biol       Date:  2006-07       Impact factor: 4.272

3.  In situ trans ligands of CD22 identified by glycan-protein photocross-linking-enabled proteomics.

Authors:  T N C Ramya; Eranthie Weerapana; Lujian Liao; Ying Zeng; Hiroaki Tateno; Liang Liao; John R Yates; Benjamin F Cravatt; James C Paulson
Journal:  Mol Cell Proteomics       Date:  2010-02-19       Impact factor: 5.911

4.  Studies on the Detection, Expression, Glycosylation, Dimerization, and Ligand Binding Properties of Mouse Siglec-E.

Authors:  Shoib Siddiqui; Flavio Schwarz; Stevan Springer; Zahra Khedri; Hai Yu; Lingquan Deng; Andrea Verhagen; Yuko Naito-Matsui; Weiping Jiang; Daniel Kim; Jie Zhou; Beibei Ding; Xi Chen; Nissi Varki; Ajit Varki
Journal:  J Biol Chem       Date:  2016-12-05       Impact factor: 5.157

Review 5.  Sialic acids and autoimmune disease.

Authors:  Vinay S Mahajan; Shiv Pillai
Journal:  Immunol Rev       Date:  2016-01       Impact factor: 12.988

Review 6.  CD22: an inhibitory enigma.

Authors:  Jennifer A Walker; Kenneth G C Smith
Journal:  Immunology       Date:  2007-12-07       Impact factor: 7.397

7.  Distinct endocytic mechanisms of CD22 (Siglec-2) and Siglec-F reflect roles in cell signaling and innate immunity.

Authors:  Hiroaki Tateno; Hongyi Li; Melissa J Schur; Nicolai Bovin; Paul R Crocker; Warren W Wakarchuk; James C Paulson
Journal:  Mol Cell Biol       Date:  2007-06-11       Impact factor: 4.272

8.  Bifunctional CD22 ligands use multimeric immunoglobulins as protein scaffolds in assembly of immune complexes on B cells.

Authors:  Mary K O'Reilly; Brian E Collins; Shoufa Han; Liang Liao; Cory Rillahan; Pavel I Kitov; David R Bundle; James C Paulson
Journal:  J Am Chem Soc       Date:  2008-05-28       Impact factor: 15.419

9.  An extracatalytic function of CD45 in B cells is mediated by CD22.

Authors:  Sarah Coughlin; Mark Noviski; James L Mueller; Ammarina Chuwonpad; William C Raschke; Arthur Weiss; Julie Zikherman
Journal:  Proc Natl Acad Sci U S A       Date:  2015-11-11       Impact factor: 11.205

10.  Simultaneously targeting CD45 significantly increases cytotoxicity of the anti-CD33 immunoconjugate, gemtuzumab ozogamicin, against acute myeloid leukemia (AML) cells and improves survival of mice bearing human AML xenografts.

Authors:  Roland B Walter; Kelli M Boyle; Frederick R Appelbaum; Irwin D Bernstein; John M Pagel
Journal:  Blood       Date:  2008-03-07       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.